Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
Recruiting · NCT06783751 · Interventional (participants receive a specific treatment) · Lead sponsor: University of California, Irvine
View the official record on ClinicalTrials.gov →Interventions studied
Conventional Vertical Sleeve Gastrectomy (cVSG)Modified Vertical Sleeve Gastrectomy (mVSG)
What this trial is about
This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Male and female subjects aged 18-65 years
- Body mass index (BMI) 35-55 kg/m2
- Must meet the BMI criteria before and after 6 months of nonsurgical weight management
- Presence of GERD defined for this trial as acid exposure time (AET) of 4.9% or above as assessed with the Bravo pH test.
- Have health insurance which pays for the costs of bariatric surgery and standard medical care before and after surgery
- Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry and prior to surgery
- Must be able to provide written informed consent
Exclusion criteria
- Hiatal hernia \>2cm (defined as maximum axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at the time of surgery)
- Evidence of clinically significant major esophageal motility disorder as determined by the site primary investigator
- Severe gastroparesis
- Previous bariatric or anti-reflux procedure
- Barrett's esophagus
- Subjects requiring mesh treatment at time of procedure
- Severe heart (e.g., severe heart failure, unstable coronary artery disease), or end-stage lung disease as determined by the site primary investigator
- Subjects with pacemakers, implantable defibrillators, neurostimulators
- Portal hypertension or cirrhosis
- Chronic pancreatitis
- Active cancer treatment
- Inability to tolerate general anesthesia
- Uncontrollable coagulopathy
- Significant and uncontrolled inflammatory bowel disease
- Severe and/or uncontrolled psychiatric disorder (including psychosis, bipolar disorder) as determined during standard pre-surgery psychiatric screening at the site.
- Suicidal ideation or unstable/untreated major depressive disorder within the past year
- Alcohol or substance use disorder within the past year.
- Pregnant or breastfeeding or planning pregnancy in the coming 24 months
- Diminished intellectual capacity to consent or follow pre- and post-surgery instructions
- History of, or any current health condition that, in the opinion of the PI, would make the subject ineligible for sleeve gastrectomy, or put the subject at risk by participation in the study.
Where it is running
2 locations listed across 1 US state.
- University of California, Irvine - Orange, California, United States
- University of California, San Diego - San Diego, California, United States